Jupiter Neurosciences (#JUNS) entered into a definitive license agreement with PharmAla Biotech for exclusive, perpetual U.S. rights to ALA-002, a patented non-racemic MDMA formulation. The transaction is valued at up to $100 million, including upfront and milestone payments, giving Jupiter rights to develop, manufacture and commercialize ALA-002 in the United States. Sector: Biotechnology / CNS Therapeutics Key Highlights 🤝 Definitive license agreement with PharmAla Biotech 🇺🇸 Exclusive, perpetual U.S. rights 💊 Asset: ALA-002 💰 Transaction value of up to $100M 📈 Includes upfront and milestone payments 🧪 Rights cover development, manufacturing and commercialization 🧠 Strengthens Jupiter's CNS drug-development pipeline Why It Matters The licensing agreement expands Jupiter's CNS pipeline and gives the company U.S. development and commercialization rights to a potentially differentiated MDMA-based therapeutic candidate. Read More: https://www.thinksabio.com/reports/isr/JUNS